{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetics%2C+Chronic+Kidney+Disease%2C+Protein+in+Urine",
    "query": {
      "condition": "Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T04:27:12.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01464320",
      "title": "A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine"
      ],
      "interventions": [
        {
          "name": "ABT-614",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-11",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-08-22",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464320"
    },
    {
      "nct_id": "NCT00552409",
      "title": "Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Chronic Kidney Disease",
        "Diabetic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2007-12",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2014-04-28",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00552409"
    },
    {
      "nct_id": "NCT01356849",
      "title": "Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Atrasentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2011-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 59,
      "location_summary": "Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01356849"
    },
    {
      "nct_id": "NCT03502031",
      "title": "Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Insufficiency, Chronic",
        "Diabetic Nephropathy Type 2"
      ],
      "interventions": [
        {
          "name": "Renin-Angiotensin (RAAS) alone",
          "type": "DRUG"
        },
        {
          "name": "Renin-Angiotensin (RAAS) blockers in combination with Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James A. Tumlin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "75 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "75 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2018-10-01",
      "completion_date": "2024-10-01",
      "has_results": false,
      "last_update_posted_date": "2022-10-28",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 2,
      "location_summary": "Lawrenceville, Georgia • Bethlehem, Pennsylvania",
      "locations": [
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03502031"
    },
    {
      "nct_id": "NCT00920764",
      "title": "A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Placebo for Atrasentan 0.2 mg/mL solution",
          "type": "DRUG"
        },
        {
          "name": "0.25 mg Atrasentan QD",
          "type": "DRUG"
        },
        {
          "name": "0.75 mg Atrasentan QD",
          "type": "DRUG"
        },
        {
          "name": "1.75 mg Atrasentan QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2009-06",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 24,
      "location_summary": "Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920764"
    },
    {
      "nct_id": "NCT05570305",
      "title": "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Zibotentan",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin and Zibotentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Medical Center Groningen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-10-06",
      "completion_date": "2025-03-05",
      "has_results": false,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570305"
    },
    {
      "nct_id": "NCT07348718",
      "title": "Rubix LS Diabetic Kidney Disease (DKD) Registry Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Kidney Disease (DKD)"
      ],
      "interventions": [
        {
          "name": "Kidney-Protective Therapies Used in Routine Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rubix LS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2025-12-15",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-10-09T04:27:12.243Z",
      "location_count": 1,
      "location_summary": "Lawrence, Massachusetts",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348718"
    }
  ]
}